Market research
HEMO.LSE Hemogenyx Pharmaceuticals Plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 30M
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.49
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BYX3WZ24
- Market cap
- 30M
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.49
About
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. The company also treats for solid and rare cancers; and immune system and autoimmune diseases. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HEMO.LSE discussion.
5 years, 5 months ago
Hemogenyx Pharmaceuticals Plc is currently in a long term downtrend where the price is trading 66.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Hemogenyx Pharmaceuticals Plc gets an overall score of 1/5.